碳酸镧治疗血液透析患者顽固性高磷血症的前瞻性观察  

Efficacy and side effects of lanthanum carbonate in the treatment of refractory hyperphosphatemia in dialysis patients

作　　者：华青[1] 陈强[1] 计文明[1] 黎曼[1] 

机构地区：[1]江苏省苏州市立医院北区肾内科,苏州215008

出　　处：《南通大学学报（医学版）》2014年第2期101-103,共3页Journal of Nantong University(Medical sciences)

摘　　要：目的 :观察碳酸镧治疗血液透析患者顽固性高磷血症的有效性和安全性。方法 :选择16例存在顽固性高磷血症的维持性血液透析(maintenance hemodialysis,MHD)患者,每日3餐餐中予嚼服碳酸镧咀嚼片500 mg,4周后对血磷水平进行分析评估,并观察不良反应。结果:患者口服碳酸镧4周后血磷水平明显下降,血清磷水平由服药前(2.99±0.26)mmol/L降为(1.94±0.28)mmol/L(P<0.05),而血清钙、甲状旁腺激素等指标在治疗前后并无明显变化(P>0.05)。在服用碳酸镧过程中,2例患者出现轻微的胃部不适感,但无1例患者因严重的不良反应中断治疗。结论:碳酸镧能够安全和有效地降低MHD患者的血磷水平。Objective： To assess the efficacy and side effects of lanthanum carbonate in maintenance hemodialysis（MHD） patients with refractory hyperphosphatemia. Methods： Sixteen MHD patients with refractory hyperphosphatemia were prescribed with lanthanum carbonate 500 mg for 4 weeks, three times a day in mealtime. The serum phosphorus was examined before and after treatment and the side effects was also observed. Results： After treatment, serum phosphorus decreased significantly from（2.99±0.26） mmol/L to（1.94±0.28） mmol/L（P0.05）. The serum calcium,and serum parathyroid hormone show no obvious variation（P0.05）. The side effects of lanthanum carbonate were weak, only 2 patients feel sick to their stomach. No patient interrupted therapy and no serious adverse events were observed. Conclusion： The management of hyperphosphatemia with lanthanum carbonate in MHD patients is safe and effective.

关 键 词：顽固性高磷血症 维持性血液透析 碳酸镧 

分 类 号：R589.5[医药卫生—内分泌]